The field of adolescents and young adults (AYA) oncology is experiencing a very challenging time. This book is a guide to the key issues for any clinician and health professional managing AYA with cancer in Europe. Emphasis is on collaboration between adult and pediatric specialists. Authors present their perception of the current state of the most prominent primary issues in AYA oncology.

Chapters cover cross-cutting issues such as disease epidemiology, systems of care, access to innovative therapy and late effects of treatment and survivorship for AYA-onset cancers. There are discussions of the latest developments and the most important cancer types in AYA, including the shared perspectives of adult and pediatric specialists. Throughout the book recurrent challenges to the AYA community are exposed and solutions proposed.

Tumors in Adolescents and Young Adults is highly recommended to any oncologist or hematologist treating patients aged 15 to 39 diagnosed with cancer. It will also be of interest to other members of the multidisciplinary teams involved with this patient group.

Contents
Preface: Stark, D.P.; Vassal, G.

Cross-Cutting Issues
- Epidemiology of Adolescents and Young Adults with Cancer in Europe: Desandes, E.; Stark, D.P.
- Supportive Care: Olsen, P.R.; Lorenzo, R.
- Long-Term Follow-Up and Survivorship: Tsiroli, A.; Hjorth, L.
- Increasing Access to Clinical Trials and Innovative Therapy for Teenagers and Young Adults with Cancer – A Multiple Stakeholders and Multiple Steps Process: Gaspar, N.; Fern, L.
- Collaboration and Networking: Husson, O.; Manten-Horst, E.; van der Graaf, W.T.A.

Specific Illnesses
- Adult Cancers in Adolescents and Young Adults: Laurence, V.; Marples, M.; Stark, D.P.
- Pediatric Cancers and Brain Tumors in Adolescents and Young Adults: McCabe, M.G.; Valteau-Couanet, D.
- Leukemia: Julliasson, G.; Hough, R.
- Lymphoma in Adolescents and Young Adults: Brugieres, L.; Brice, P.
- Germ Cell Tumors in Adolescents and Young Adults: Calaminus, G.; Joffe, J.
- Sarcomas of Soft Tissue and Bone: Ferrari, A.; Dirksen, U.; Bielack, S.

Author Index
Subject Index

The easiest way to order: www.karger.com/pritr
Chemotherapy

International Journal of Experimental and Clinical Chemotherapy

Founded 1959 as 'Chemotherapia' by H.P. Kuemmerle and P. Rentchnick

Editor-in-Chief
G. Minotti, Rome

Associate Editors
G. Delogu, Rome
G. Graziani, Rome

Editorial Board
A.M. Biroccio, Rome
C. Chiesa, Rome
S. Gemma, Siena
S. Horkovics-Kovats, Kundl
S. Kohno, Nagasaki
C. Landersdorfer, Parkville, Vic.
P. Linder, Geneva
K. Machka, Munich
P. Menna, Rome
E. Monti, Busto Arsizio
K.G. Naber, Straubing
R. Nau, Göttingen
P. Preziosi, Rome
E. Salvatorelli, Rome
M. Sanguinetti, Rome
G. Sava, Trieste
G.M. Shah, Quebec, Que.
F. Sörgel, Nuremberg-Heroldsberg
J.C. Stingl, Bonn
F. Van Bambeke, Brussels
M. Wilhelm, Nuremberg

The founder of chemotherapy

Paul Ehrlich
1854–1915
Guidelines for Authors

Submission
Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

A Copyright Transfer Form, available on the Submission Website, with the corresponding author's original (hand-written) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Names, postal and e-mail addresses of 4 international experts in the appropriate area of research should accompany each manuscript. At the Editors’ discretion, scientist(s) selected from this list may be invited to act as referee(s). Referees suggested should not be from the same institution as the author.


In case of problems with submission, please contact:

che@karger.com

S. Karger AG – Medical and Scientific Publishers
Editorial Office ‘Chemotherapy’
Allschwilerstrasse 10
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434

Conditions
All manuscripts are subject to editorial and peer review. Manuscripts are received with the explicit understanding that the work has not been published (wholly or in part), and is not under simultaneous consideration in any language elsewhere. Furthermore, all authors have made substantial contributions and confirm that they have seen and approved the manuscript submission. Submission of an article for publication implies the transfer of the copyright from the author to Karger Publishers upon acceptance. Accepted manuscripts (maximum 1,600 words) and figures must contain all the text elements in the following order: title page, the manuscript, the tables and the figures. The preferred word processing program is MS-Word. The abstract, the manuscript, the figures, tables and the figures must be submitted in separate files. The manuscript file must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledgments, references, table and figure legends. Tables and figures should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title page: Title page shall contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc. where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Background/aims, Methods, Results, Conclusions. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained at the first mention. They should be numbered consecutively and appear at the foot of the appropriate page.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lower-case) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript registration symbol ® or ™ when they are first mentioned.

Tables and illustrations: Tables and figures must be numbered (e.g. Figure 1, Figure 2) and submitted as separate files. Tables require a heading and figures a legend, which must provide sufficient information for either to stand alone. Each figure and table must be cited in the text numerically. Tables should be in Word format. b/w/half-tone and color figures must have a final resolution of 300 dpi after scaling to final size, line drawings 1200 dpi. Color figures must be in RGB format. All figures should be in a common format such as PDF, TIF, PNG, EPS or WMF. Vector graphics should be in PPT, AI or EPS format.

Submission

Ethics
Research must comply with the guidelines for human studies and animal welfare regulations. Manuscripts reporting studies on human subjects should include evidence that the research was ethically conducted in accordance with the Declaration of Helsinki (World Medical Association; http://www.wma.net/en/30publications/10policies/b3/index.html). In particular, authors should state in the Materials and Methods section that subjects have given their informed written consent and that the study protocol was approved by an appropriate ethics committee. All patients should be identified by numbers or aliases, not by their real names. Authors should also state that animal experimentation was approved by an independent ethics committee. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. Karger Publishers defines plagiarism as reproduction of another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Sections
Authors should indicate in the cover letter which manuscript type is being submitted for publication:

Original Papers: Fully documented reports of original research that must describe full sets of significant, original experiments in current anti-infective and antitumor chemotherapy research. Abstract, Introduction, Materials and Methods, Results, and Discussion sections are required. Consideration for publication is based on originality, novelty, scientific soundness, and appropriate analysis (maximum 3,000 words, 80 references, plus tables/figures).

Reviews: Comprehensive, state-of-the-art papers covering a timely topic by experts in the field (maximum 4,000 words, plus tables/figures, references). Reviews are usually invited by the Editor but may be unsolicited. Authors are asked to contact the Editor-in-Chief before submission in order to avoid clashes with other pending reviews. All reviews are subject to peer review. An unstructured abstract of no more than 200 words is required.

Novel Insights from Clinical Practice: The journal only considers case reports that provide significant new insights into a clinical problem or with an extremely unusual clinical course. Submissions can be based around a case or a number of similar cases. The most important aspect of the presentation is that it should provide a new perspective on a recognized clinical scenario or may represent an entirely new clinical condition. The novel aspects of the case(s) may be in the phenotype, the presentation, the investigation and/or the management. The manuscript should contain an unstructured abstract (maximum 150 words), introduction, case report and discussion section (maximum 2,000 words, maximum 2 tables or figures). Boxes containing bulleted points on Established Facts (what is already known) and Novel Insights (new information gained) are required on the first page of the report. These should highlight the novelty of the clinical observation.

Short Communications: Short reports, brief laboratory observations, and preliminary communications can be submitted for accelerated publication under Short Communications. They must present new findings of sufficient importance to justify their accelerated acceptance. Such communications should represent complete, original studies and should be arranged in the same way as full length manuscripts (maximum 1,600 words).

Letters to the Editor: Letters to the Editor are encouraged if they directly concern articles recently published in this journal. If accepted, the Editor reserves the right to submit such letters to the authors of the articles concerned prior to publication in order to allow them to respond in the same issue of the journal. In exceptional cases, Letters to the Editor may also address data published in another journal or general subjects related to matters discussed in the journal. No abstract is required (maximum 1,200 words).

Arrangement
The preferred word processing program is MS-Word. The cover letter, the manuscript, the tables and the figures must be submitted in separate files. The manuscript file must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledgments, references, table and figure legends. Tables and figures should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title page: Title page shall contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc. where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Background/aims, Methods, Results, Conclusions. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained at the first mention. They should be numbered consecutively and appear at the foot of the appropriate page.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lower-case) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript registration symbol ® or ™ when they are first mentioned.

Tables and illustrations: Tables and figures must be numbered (e.g. Figure 1, Figure 2) and submitted as separate files. Tables require a heading and figures a legend, which must provide sufficient information for either to stand alone. Each figure and table must be cited in the text numerically. Tables should be in Word format. b/w/half-tone and color figures must have a final resolution of 300 dpi after scaling to final size, line drawings 1200 dpi. Color figures must be in RGB format. All figures should be in a common format such as PDF, TIF, PNG, EPS or WMF. Vector graphics should be in PPT, AI or EPS format.
General Information

Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.

Personal subscription:
- Print or Online: CHF 1232.00
- Postage and handling: CHF 45.60, Europe, CHF 67.20 Overseas
- EUR 1027.00
- USD 1257.00

Print or Online combined:
- CHF 1280.00
- EUR 1066.00
- USD 1305.00

Institutional subscription:
- Print or Online: CHF 2464.00
- Postage and handling: CHF 57.00, Europe, CHF 84.00 Overseas
- EUR 2053.00
- USD 2514.00

Print or Online combined:
- CHF 2834.00
- EUR 2361.00
- USD 2891.00

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including Current Contents® and PubMed/MEDLINE.

Photocopying: This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, MA 01923 (USA).

A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, P.O. Box CH–4009 Basel (Switzerland).

Change of Address:
Both old and new address should be sent to the subscription source.

Photo of Paul Ehrlich on inner title page
Courtesy of the Paul-Ehrlich-Institute, Langen, Germany
Contents

See the journal website for contents
Respiration brings together the results of both clinical and experimental investigations on all aspects of the respiratory system in health and disease. Clinical improvements in the diagnosis and treatment of chest and lung diseases are covered, as are the latest findings in physiology, biochemistry, pathology, immunology and pharmacology. The journal includes classic features such as editorials that accompany original articles in clinical and basic science research, reviews and letters to the editor. Further sections are: The Eye Catcher, What’s Your Diagnosis?, New Insights from Clinical Practice

Respiration

Editor-in-Chief
F.J.F. Herth, Heidelberg

Associate Editors
I. Adcock, London
K.E. Bloch, Zurich
A. Boehle, Zurich
D. Bouros, Athens
A. Chetta, Parma
V. Cottin, Lyon
C. Dooms, Leuven
E. Eber, Graz
S. Gasparini, Ancona
J. Hammer, Basel
J. Johnston, Vancouver, B.C.
C.F. Koegelengen, Cape Town
C. Lange, Bonstel
M. Lommatsch, Rostock
M. Miravitelles, Barcelona
J. Müller-Quernheim, Freiburg
L.P. Nicod, Lausanne
D. Oliveri, Parma
W. Randerath, Solingen
P.L. Shah, London
S. Siddiqui, Leicester
T. Terashima, Ichikawa
O.S. Usmani, London
S. van Eeden, Vancouver, B.C.
K. Yasufuku, Toronto, Ont.

More information at www.karger.com/res
Antimicrobial Section

Original Papers

295 Clarithromycin Dose-Dependently Stabilizes Rat Peritoneal Mast Cells
Kazama, I.; Saito, K.; Baba, A.; Mori, T.; Abe, N.; Endo, Y.; Toyama, H.; Ejima, Y.; Matsubara, M.; Yamauchi, M. (Sendai)

313 Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine

319 Tannic Acid as a Potential Modulator of Norfloxacin Resistance in Staphylococcus Aureus Overexpressing norA

323 Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired Pneumonia

Anticancer Section

Original Papers

281 Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Patients with Neuroendocrine Tumors: An Izmir Oncology Group Study

287 Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer
Frielink, L.M.J. (Maastricht/S-Hertogenbosch); Pijlman, B.M. (S-Hertogenbosch/Eindhoven); Ezendam, N.P.M.; Pijnenborg, J.M.A. (Eindhoven/Tilburg)

304 Dihydroergotamine Tartrate Induces Lung Cancer Cell Death through Apoptosis and Mitophagy
Chang, S.-H.; Lee, A.Y.; Yu, K.-N. (Seoul); Park, J. (Daejeon); Kim, K.P. (Yongin); Cho, M.-H. (Seoul/Daejeon/Suwon/Pyeongchang)

331 Acknowledgement to Reviewers